UNSPSC 51172807: Aluminum chloride/hydroxyquinoline sulfate/tetracaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172807 Aluminum chloride/hydroxyquinoline sulfate/tetracaine is a Commodity code covering specialty pharmaceutical and chemical compounds used in state and local healthcare and institutional settings. Based on recent solicitation activity, the code encompasses generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to participating government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in current activity, soliciting manufacturers to supply comprehensive pharmaceutical product lines with specific National Drug Codes, packaging configurations, and manufacturing documentation. Vendors must maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, hold contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, or Morris & Dickson Co., LLC), and support chargeback systems and EDI capability. Contract awards favor price competitiveness (75 percent weight), with secondary evaluation on fixed pricing, administrative fee compliance, and EDI readiness.

MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, represents the visible opportunity under this code and covers multiple state and local government facilities including Oregon as a participating jurisdiction. The solicitation establishes two-year initial terms (with optional extensions through June 30, 2028 for incumbents) and requires vendors to certify product availability by May 15, 2026, with contract effectiveness on July 1, 2026. Vendors must carry commercial general liability coverage of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, along with compliance with FDA requirements and minimum six-month shelf-life assurance. The cooperative purchasing structure and multi-award approach indicate sustained demand across member jurisdictions, though the source discloses no specific budget ranges or contract values.